Latest Patrys (ASX:PAB) News

Patrys has moved its injectable quetiapine program into human testing, while its FY2026 annual report warns the company will need further funding within 12 months. The company ended the year with $3.36 million in cash after raising capital and acquiring the RLS-2202 development program.

Patrys has dosed the first participants in the Phase 1a trial of RLS-2202, moving its intravenous quetiapine formulation into human clinical evaluation. The next test comes in October, when an independent safety committee will decide whether the program can advance to Cohort 2.

AdAlta led the healthcare board after a US cell-therapy manufacturing deal gave its automation platform commercial credibility, while Vectus fell despite reporting a profit. Clinical trial updates, diagnostic launches and fresh funding plans kept the sector active.

Patrys has formed an international Clinical Advisory Committee to help shape the next stages of RLS-2202, its injectable quetiapine candidate for delirium in acute-care settings. The appointments add recognised expertise in delirium research, intensive care and trial design, but do not yet provide clinical efficacy or regulatory evidence.

Healthcare shares split sharply this week, with Biome Australia rising while Nanosonics, Epiminder and Saluda Medical fell heavily.
Profits, trial progress and new approvals competed with cash needs, debt concerns and weaker investor confidence.

Patrys has cleared a key regulatory hurdle with Human Research Ethics Committee approval for its Phase 1A clinical trial of RLS-2202, aiming to start dosing healthy volunteers this quarter.

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.

Patrys Limited is pushing forward with a proprietary injectable formulation of quetiapine targeting the lucrative delirium treatment market, leveraging a faster, lower-cost FDA 505(b)(2) regulatory pathway and strong patent protection.

Big price swings hit healthcare stocks this week, but the sharpest falls did not always match the news flow. Revenue growth, trial progress and fresh US deals kept buying interest alive across parts of the sector.

Patrys has assigned its deoxymab intellectual property to Yale University in a deal granting it half of all future commercialisation revenue, reducing capital needs while keeping long-term upside.

Imugene, Vitasora and Adherium led a volatile week in healthcare shares, as trial news and software rollouts battled capital raisings, legal issues and weak sentiment in smaller biotech names. Big contracts, takeover steps and record earnings kept the sector busy, but several stocks still fell even after reporting clear operational progress.

Patrys has appointed CMAX and Alithia Life Sciences to lead its Phase 1A clinical trial operations for RLS-2202, advancing its injectable quetiapine program toward first-in-human testing in Q3 2026, pending ethics approval.